06.02.2025 14:12:38
|
Immuneering Signs Clinical Supply Agreement With Regeneron To Evaluate IMM-1-104 Plus Libtayo
(RTTNews) - Immuneering Corporation (IMRX), a clinical-stage oncology company, Thursday said it has signed a clinical supply agreement with Regeneron Pharmaceuticals.
The supply agreement supports the evaluation of Immuneerings' lead product candidate, IMM-1-104, in combination with Regeneron's immunotherapy drug Libtayo in patients with advanced non-small cell lung cancer (NSCLC) in its ongoing Phase 2a study.
IMM-1-104 is currently in a Phase 1/2a study in patients with advanced solid tumors including pancreatic cancer.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Immuneering Corp Registered Shs -A-mehr Nachrichten
Keine Nachrichten verfügbar. |
Analysen zu Immuneering Corp Registered Shs -A-mehr Analysen
Aktien in diesem Artikel
Immuneering Corp Registered Shs -A- | 1,76 | 2,92% |
|